Respiratory Syncytial Virus Epidemiology and Clinical Burden in High-Risk and ≥ 50-Year-Old Adults in Low- to Middle-Income Countries: An Artificial-Intelligence-Enabled Systematic Literature Review
Overall, there were considerable evidence gaps for RSV epidemiology among high-risk and ≥ 50-year-old adults in developing countries. However, available data indicate a substantial negative health impact of RSV on these populations, highlighting the need for further data generation.
Authors
- Digant Gupta (ORCID: https://orcid.org/0000-0002-1963-8886)
- Yolanda Penders (ORCID: https://orcid.org/0000-0002-7606-7987)
- Amandeep Kaur
- Adriana Guzmán-Holst (ORCID: https://orcid.org/0000-0002-6753-2541)
- Vikas Verma
- Desirée Van Oorschot (ORCID: https://orcid.org/0000-0002-0382-0333)
- Arnas Berzanskis (ORCID: https://orcid.org/0009-0005-5456-405X)
Institutions
- GlaxoSmithKline (Belgium) (BE)
- Bridge Pharma (United States) (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1007/s40121-025-01220-4
- Citations
- 2
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- GlaxoSmithKline